Clinical Trial Update: SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of SCT-001 CAR T Cells Therapy for relapsed and refractory ovarian cancer and related peritoneal cancers is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Cancer
• Peritoneal Carcinoma

Drugs mentioned

• SCT-001 CAR T Cells Therapy (SCT-001)

Snippet

Sponsor: Shanghai Gynecologic Oncology Group | Conditions: Ovarian Cancer, Fallopian Tube Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING